Enhancement Of Tumor Response To Chemotherapy By Activation Of The Asmase/Ceramide Pathway Through Timed Administration Of A Short-Acting Anti-Angiogenic Agent
Patent No. EP3217983 (titled "Enhancement Of Tumor Response To Chemotherapy By Activation Of The Asmase/Ceramide Pathway Through Timed Administration Of A Short-Acting Anti-Angiogenic Agent") was filed by Memorial Sloan Kettering Cancer Center on Nov 12, 2015. The application was issued on May 1, 2024.
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3217983
- Application Number
- EP15859462A
- Filing Date
- Nov 12, 2015
- Status
- Granted And Under Opposition
- Mar 29, 2024
- Publication Date
- May 1, 2024
- External Links
- Slate, Register , Google Patents